Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype by Boekhorst, P.A.W. (Peter) te et al.
Cancer Chemother Pharmacol (1992) 30:238-242   ancer hemotherapy and 
narmacomgy 
9 Springer-Verlag 1992 
Short communication 
Reversal of typical multidrug resistance by cyclosporin 
and its non-immunosuppressive analogue SDZ PSC 833 
in Chinese hamster ovary cells expressing the mdrl phenotype 
Peter A. W. te Boekhorst, Jan van Kapel, Martijn Schoester, and Pieter Sonneveld 
Department ofHaematology, Erasmus University Rotterdam, The Netherlands 
Received 20 December 1991/Accepted 2 March 1992 
Summary. The new non-immunosuppressive cyclosporin 
derivative SDZ PSC 833 (PSC) is a potent agent used to 
overcome typical multidrug resistance (MDR) associated 
with overexpres s ion of the mdr 1 gene encoding for a P-170 
glycoprotein. In the present study, the efficacy of PSC as 
compared with cyclosporin was determined in Chinese 
hamster ovary cell lines exhibiting different levels of resis- 
tance to colchicine (0, 0.1, 0.2 and 10 gg/ml, respectively). 
Low concentrations of PSC (8.2 riM) increased the cytotox- 
icity of colchicine in cell lines expressing low levels of 
drug resistance. The concentration resulting in 50% cell 
survival (LC50 value) found for colchicine alone or in 
combination with PSC in the CHO-A3 cell line that was 
resistant to 100 ng colchicine/ml decreased from >500 to 
200 ng/ml at 8.2 nM PSC and to <100 ng/ml at 82 and 
820 nM PSC. In the CHO-A3 cell line that was resistant to 
200 ng colchicine/ml, the LCs0 values decreased from 
>500 ng/ml for colchicine alone to 500 ng/ml for colchi- 
cine used in combination with 8.2 nM PSC and to 
<100 ng/ml for colchicine combined with 82 or 820 nM 
PSC. At a concentration f 82 nM PSC, the maximal effect 
in MDR reversal was observed in the cell lines exhibiting 
moderate resistance. In the highly resistant cell line, PSC 
(820 nM) also reversed colchicine resistance. In drug-accu- 
mulation experiments, we obtained a 4-fold increase in 
intracellular doxorubicin accumulation using 820 nM PSC. 
A comparison of PSC with cyclosporin revealed that a 
cyclosporin concentration 20-fold that of PSC was re- 
quired to obtain the same sensitising effect. On the basis of 
these data, it may be concluded that PSC is a most promis- 
ing chemosensitiser. 
Introduction 
Multidrug resistance (MDR) characterised by reduced 
drug accumulation in resistant cells as compared with their 
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drug-sensitive parental cells is often associated with in- 
creased expression of a 170-kDa transmembrane glyco- 
protein (P-glycoprotein, Pgp) [3, 10]. The level of Pgp 
expression is correlated with the level of drug resistance 
and reflects the decreased accumulation f anthracyclines 
and vinca alkaloids [3, 11, 14]. In a variety of human 
malignancies, the mdrl gene that encodes for Pgp is ex- 
pressed at increased levels [8]. In vitro, the lowered drug 
accumulation can be reversed by numerous agents, includ- 
ing calcium antagonists such as verapamil, calmodulin i - 
hibitors and cyclosporin A (CsA) [4, 9, 13-15]. Some of 
these agents have recently entered clinical trials [5, 16, 18]. 
Recently, SDZ PSC 833 (PSC; mol. wt., 1,214.65 Da), a 
new cyclosporin D analogue, was introduced as a che- 
mosensitiser. PSC is described as being more potent han 
CsA [2, 7]. It lacks the nephrotoxic and haemodynamic 
side effects of CsA and has been purported to be non-im- 
munosuppressive [1].
In the present study, we investigated the sensitisation f 
Chinese hamster ovary (CHO) cell lines expressing differ- 
ent levels of Pgp in association with the MDR phenotype 
using various PSC concentrations, and we compared these 
findings with the sensitisation btained using CsA. In addi- 
tion, the effect of PSC preincubation on the intracellular 
accumulation fthe Pgp-associated drug doxorubicin was 
evaluated ina Pgp-expressing CHO MDR cell line. 
Materials and methods 
Drugs and chemicals. Doxorubicin (DOX; Farmitalia, Milan, Italy) and 
daunorubicin (DNR; Rhone-Poulenc Pharma, France) were dissolved in 
sterile distilled water to a concentration f 1 mg/ml and were stored as 
aliquots at -80 ~ C. Dilutions were made in either sterile water or 1 M 
TRIS buffer (pH 8.8) immediately before use. Colchicine (COL; Sigma, 
St. Louis, Mo., USA) was dissolved in dimethylsulphoxide (DMSO; 
Merck, Darmstadt, FRG) at 200 mg/ml and stored at -80~ PSC 
(Sandoz, Basel, Switzerland) and CsA (Sandoz) were dissolved in abso- 
lute ethanol at 5 mg/ml and stored at 4 ~ Dilutions were made in 
medium immediately before use. Methanol and chloroform were obtain- 
ed from Rathburn (Walkerburn, Scotland) and glacial acetic acid was 
supplied by Merck; all were of analytic grade. Desipramine was obtained 
from Sigma. 
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Cells and medium. The CHO cell line grows as an attached monolayer on 
plastic. The parent cell line, CHO-AUX B 1, was cultured in c~-minimum 
essential medium (t~-MEM; Gibco, Paisley, UK) supplemented with 
gentamycin (60 gg/ml, Gibco) and 10% foetal calf serum (FCS, Gibco). 
MDR sublines were derived by in vitro growth of the parent line in 
increasing concentrations of COL. The sublines were routinely cultured 
in COL at concentrations of 100, 200 (CHO-A3) or 10,000 ng/ml (CHO- 
C5). The cell lines were maintained as stock cultures in 162-cm 2 flasks 
incubated at37 ~ C in a fully humidified atmosphere comprising 5% CO2 
in air. A single-cell suspension was produced by removal of the adherent 
cells by scraping followed by their incubation with 0.1% (w/v) col- 
lagenase (Sigma) at 37~ for 30 min. Finally, the collagenase-treated 
cells were washed twice in medium. 
Immunohistochemistry studies. For the determination f Pgp expression, 
the monoclonal ntibody C219 (Centocor, Malveru, Pa., USA) was used. 
Cytospin preparations of the CHO cell lines were prepared and air-dried 
for 18 h. They were fixed in methanol/acetone (50/50%), soaked in 
50 mu TRIS in 0.02% Tween-20 for 5 rain and incubated with 10% 
rabbit +1% goat serum for 30 min. Undiluted C219 monoclonal ntibody 
or mouse IgGza (Coulter, USA) was added and the preparations were 
incubated overnight at 4 ~ C. Antimouse immunoglobulin was added to 
each slide, the slides were washed, and the cells were then incubated with 
alkaline phosphatase substrate (APAAP) for 60 min at 37 ~ C and washed 
three times. 
MTTassay. The in vitro sensitivity of the cell lines to COL in the absence 
or presence of various concentrations of PSC was determined using a 
modification ofthe assay originally described by Mosmann [ 12]. Briefly, 
a single-cell suspension f5 x 104 cells/ml medium supplemented with 
10% FCS was prepared for all cell lines. Then, 200-gl aliquots of the 
suspension were dispensed into 90-well flat-bottomed microtiter plates 
(Costar, Cambridge, Mass.). After 2 h incubation, the appropriate doses 
of PSC, CsA or solvent control (ethanol, 0.02% v/v) were added to the 
wells in a volume of 10 gl. After 1 additional h incubation, COL or 
solvent control (DMSO, 0.005% v/v) was added in a further volume of 
10 gl. In these xperiments four replicate wells were used at each point. 
The plates were incubated for 68 h. Next, 30 gl of a 5-mg/ml solution of 
MTT (Sigma) was added to each well and the plates were incubated for 
another 4 h. The plates were then centrifuged for 10 min at 500 g. After 
removal of the supernatants, theformazan crystals were dissolved with 
100 gl DMSO. The optical density (OD) of the wells was measured 
using a Titertek multiscan plate reader (Flow) at 540 nm. The percentage 
of cell survival was defined as the mean OD of treated wells divided by 
the mean OD of untreated control wells x 100%. The LCs0 value, de- 
fined as the drug concentration resulting in 50% cell survival, was 
derived by calculating the point at which the dose-response curve crossed 
the point of 50% cell survival. The CHO-A3 (100 rig) subline was used 
for purposes of comparing PSC with CsA. 
Drug accumulation. The effect of PSC on intracellular d ug accumula- 
tion was studied in the CHO-A3 (100 ng) cell line using DOX. After 2 h 
incubation of 107 cells in 75-cm 2flasks, PSC was added (final concen- 
tration, 0, 8.2 or 820 nu). The cells were incubated for 1 additional h 
prior to the addition of DOX (final concentrations, 50, 250 or 
1,000 ng/ml). After an incubation period of 30, 60 or 120 min, the 
monolayers were washed twice with phosphate-buffered saline (PBS, 
Gibco). Next, the ceils were collected by scraping; after centrifugation, 
the cell pellets were stored at-80 ~ C until their analysis by high-perform- 
ance liquid chromatography (HPLC) using a procedure described else- 
where [17]. 
Extraction procedure and HPLC analysis for DOX in cells. The thawed 
cell pellets, supplemented with 250 gl PBS and internal standard (DNM), 
were sonicated at120 W for 2 min (Eurosonic 44, FRG). The suspension 
was extracted twice with 4 ml chloroform/methanol (9: I, v/v). Follow- 
ing centrifugation at 1,000 gfox" 10 rain, the two chloroform phases were 
collected and evaporated in one step at 37~ under nitrogen. The dry 
residue was dissolved in 1 ml chloroform/methanol (9 : 1, v/v), the solu- 
tion was centrifuged for 10 min at 1,000 g and 500 gl was injected onto 
the chromatographic column. 
The chromatographic system consisted of a Dupont Instruments 870 
pump module and a sampling valve equipped with a sampling loop of 
500 gl. The analytic olumn (200 mm x 3 mm inside diameter) was 
packed with spherical silica gel Lichrosorb Si-60 (partical size, 7 gin; 
Chrompack). Fluorescence detection (Shimadzu spectrofluorometer 
RF-510) was carried out using an excitation wavelength of488 nm and 
an emission wavelength of 550 rim. The column was eluted with 
chloroform/methanol/glacial etic acid/water (720 :210:40 : 30, by 
vol.) supplemented with 0.3 mM MgC12 and 10 gg desipramine/ml at a 
flow rate of 0.5 ml/min. The integration of the peaks was performed 
using a Spectra-physics SP 4270 integrator. Quantification f the cellular 
drug concentration was achieved by measuring the peak-height ratio of 
DOX and the internal standard and was calculated from a calibration 
curve for peak height versus concentration. 
Results 
The Pgp expression was determined by immunocyto- 
chemical staining using the C219 monoclonal  antibody for 
each CHO cell l ine tested during the experiments. The 
parental CHO-AUX B 1 cells showed no staining, whereas 
the CHO-A3 (100 ng) subline showed a faint but distinct 
membrane staining. The staining of the CHO-A3 (200 ng) 
cells was more distinct han that of the CHO-A3 (100 ng) 
cells. The highly resistant CHO-C5 subline showed a 
strongly positive staining. The positivity of the staining 
reaction was clearly associated with the level of COL resis- 
tance of the cell lines. 
The in vitro sensitivities of the various CHO cell lines to 
COL in combination with PSC are shown in Fig. 1. The 
addition of different PSC concentrations or of solvent con- 
trols without COL to the cultures produced no significant 
cytotoxic effects on the cell lines tested (data not shown). 
At the lowest dose (8.2 nM), PSC increased the cytotoxic 
effects of COL on the CHO parent line. With increasing 
drug resistance of the cell lines, higher PSC concentrations 
were needed to reverse the drug resistance. The LC50 
values for the CHO-A3 (100 ng) subline decreased from 
>500 ng COL/ml alone to about 200 ng COL/ml at 8.2 nM 
PSC and to <100 ng COL/ml at 82 and 820 nM PSC. For 
the CHO-A3 (200 ng) subline, the same results were ob- 
tained except for the 8.2 nM PSC concentration, at which 
the LCs0 value was 500 ng COL/ml. The LCs0 values for 
the CHO-C5 cell l ine decreased to 500 ng COL/ml at 
820 nM PSC. 
For HPLC analysis of cellular drug accumulation, the 
detection limit of the method used was 10 ng DOX/ 
5 x 106 cells. After 2 h incubation with DOX at 250 or 
1,000 ng/ml, a 4-fold increase in cellular DOX accumula- 
tion could be achieved using 820 nM PSC in comparison 
with solvent alone. Cellular DOX-accumulat ion data are 
summarised in Table 1. 
The studies in the CHO-A3 (100 ng) subline using CsA 
instead of PSC showed that a concentration f 820 nM CsA 
could effectively increase COL cytotoxicity. The LCs0 
values were >500 ng COL/ml at a CsA concentration of
8.2 riM, about 500 ng COL/ml at 82 nM CsA and <100 ng 
COL/ml at 820 nM CsA. The relative sensitisation of the 
CHO-A3 (100 ng) resistant subline using CsA and PSC is 
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Fig. 1. Effect of colchicine in the presence orabsence of different PSC concentrations on the survival of CHO cells. II1~, 0 rtM; NNN, 8.2 riM; ~,  
82 nu; ~ ,  820 nM. Data represent mean values 4- SD for four replicate wells 
Table 1. Cellular DOX accumulation in the CHO-A3 (100 ng) subline 
exposed to DOX combined with PSC 
Incubation concentration Incubation period 
30 rain 60 rain 120 min 
DOX 50 ng/ml: 
PSC 0 nM <10 <10 <10 
PSC 8.2 tam <10 <10 <10 
PSC 820 rLM <10 <10 15 
DOX 250 ng/ml: 
PSC 0 nM 11 14 16 
PSC 8.2 rim 15 20 22 
PSC 820 nM 20 53 62 
DOX 1000 ng/ml: 
PSC 0 nM 33 50 73 
PSC 8.2 nM 48 45 98 
PSC 820 nM 97 147 307 
Values represent the cellular accumulation f DOX in ng/5 x 106 cells 
shown in Fig. 2. The results of this experiment indicate that 
PSC is about 20 times more effective than CsA in modulat- 
ing drug resistance. 
Discussion 
In the present study, we evaluated the MDR modulatory 
effects of PSC on CHO cell lines expressing different 
levels of drug resistance. The parental, non-drug-resistant 
CHO-AUX B 1 cell line used in this study expresses low 
physiological levels of Pgp [ 10] that cannot be detected by 
staining with the C219 monoclonal antibody. In agreement 
with this observation, we observed a minor increase in 
cytotoxicity using PSC at a concentration as low as 8.2 ng. 
This low dose of PSC also increased cytotoxicity in the 
CHO-A3 (100 ng) subline. The LCs0 values decreased 
from >500 ng/ml for COL alone to about 200 ng/ml for 
COL with 8.2 nM PSC. However, for complete reversal of 
COL resistance, 82 nM PSC had to be used (LCs0, <100 ng 
COL/ml). This PSC concentration also reversed rug resis- 
tance in the CHO-A3 (200 ng) subline (LCs0, <100 ng 
COL/ml). The highly resistant CHO-C5 subtine showed a 
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Fig. 2 A - C. Effect of concentrations of A 8.2 nM, B 82 nM and C 820 nM 
CsA ( 1 ) and PSC ( ~ ) in the presence of colchicine on the survival 
of the CHO-A3 (100 ng) subline. Data represent mean values ___ SD for 
four replicate wells 
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response in the form of increased cytotoxicity at 820 nM 
PSC (LCs0, 500 ng COL/ml). These results indicate that 
with increased expression of Pgp in the cell lines [10], 
higher PSC concentrations were required to obtain effec- 
tive reversal of the drug resistance. Because Pgp expres- 
sion in many human malignancies is lower than that in the 
drug-resistant CHO sublines used in the present study, [8] 
the effective PSC concentrations eeded to reverse drug 
resistance in vivo in humans may well be below 82 nM. In 
contrast, the effective CsA concentrations should be near 
820 nM [Sonneveld et al., submitted for publication]. 
Prior studies by Gavdriaux et al. [6] have demonstrated 
a significant Pgp modulation effect by CsA at 840 nM in 
the CHO parental and weakly resistant cell lines, which is 
comparable with our results. Using the weakly resistant 
CHO-A3 (100 ng) subline, which was chosen because its 
level of resistance is clinically relevant [Sonneveld et al., 
submitted for publication], we compared the efficacy of 
PSC and CsA. The results indicated that a CsA concentra- 
tion about 20-fold that of PSC was required to obtain the 
same sensitising effect. 
To exclude a direct effect of PSC on cell survival in 
these cell lines, we investigated the effect of PSC on drug 
accumulation. Previoulsy, aconsiderable, 3-fold enhance- 
ment of DNR accumulation by 500 nM CsA was reported 
in a CHO-A3 (100 rig) cell line [14]. In our drug-accumu- 
lation experiments, we obtained a minor increase in DOX 
accumulation using 8.2 nM PSC, whereas a4-fold increase 
in cellular DOX acumulation was achieved using 820 nM 
PSC. 
Clinical studies have indicated that CsA can be an effec- 
tive Pgp-modulating a ent [16, 18]. Because PSC, in con- 
trast to CsA, produces neither toxic side effects such as 
nephrotoxicity nor haemodynamic s de effects [1], higher 
doses can presumably be used to reverse or prevent he 
development of multidrug resistance. From the present 
data, we conclude that PSC is capable of reversing drug 
resistance caused by overexpression f Pgp. PSC was 
shown to be a much more potent sensitiser in comparison 
with CsA. These observations and the results of previous in 
vivo experiments [1] indicate that PSC can be of important 
clinical use in reversing drug resistance. 
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